Benzinga | Jan 18, 2022 08:55AM EST

Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $215

Morgan Stanley maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $226 to $215.